Save information for later
Sign Up

Learn About Spastic Ataxia Charlevoix-Saguenay Type

View Main Condition: Movement Disorders

What is the definition of Spastic Ataxia Charlevoix-Saguenay Type?

Autosomal recessive spastic ataxia of Charlevoix-Saguenay, more commonly known as ARSACS, is a condition affecting muscle movement. People with ARSACS typically have abnormal tensing of the muscles (spasticity), problems with balance and coordination (cerebellar ataxia), and reduced sensation and weakness in the arms and legs (peripheral neuropathy).

What are the causes of Spastic Ataxia Charlevoix-Saguenay Type?

Mutations in the SACS gene cause ARSACS. The SACS gene provides instructions for producing a protein called sacsin. Sacsin is primarily found in cells in the brain, skin, and muscles used for movement (skeletal muscles), but the specific function of the protein is unknown. Research suggests that sacsin plays a role in organizing proteins into bundles called intermediate filaments. Intermediate filaments provide support and strength to cells. In nerve cells (neurons), specialized intermediate filaments called neurofilaments comprise the structural framework that establishes the size and shape of nerve cell extensions called axons, which are essential for transmission of nerve impulses to other neurons and to muscle cells.

How prevalent is Spastic Ataxia Charlevoix-Saguenay Type?

The incidence of ARSACS in the Charlevoix-Saguenay region is estimated to be 1 in 1,500 to 2,000 individuals. Outside of Quebec, the incidence of ARSACS is unknown. About 200 individuals with ARSACS have been described in the scientific literature.

Is Spastic Ataxia Charlevoix-Saguenay Type an inherited disorder?

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Who are the top Spastic Ataxia Charlevoix-Saguenay Type Local Doctors?
Elite in Spastic Ataxia Charlevoix-Saguenay Type
Elite in Spastic Ataxia Charlevoix-Saguenay Type
Sherbrooke, QC, CA 

Cynthia Gagnon practices in Sherbrooke, Canada. Ms. Gagnon is rated as an Elite expert by MediFind in the treatment of Spastic Ataxia Charlevoix-Saguenay Type. Her top areas of expertise are Myotonic Dystrophy Type 2, Myotonic Dystrophy, Paramyotonia Congenita, and Spastic Ataxia Charlevoix-Saguenay Type.

Elite in Spastic Ataxia Charlevoix-Saguenay Type
Elite in Spastic Ataxia Charlevoix-Saguenay Type
Centre Intégré Universitaire De Santé Et De Services Sociaux Du Saguenay Lac St Jean, 2230 De L'Hôpital, Cp 1200, 
Jonquiere, QC, CA 

Isabelle Lessard practices in Jonquiere, Canada. Ms. Lessard is rated as an Elite expert by MediFind in the treatment of Spastic Ataxia Charlevoix-Saguenay Type. Her top areas of expertise are Spastic Ataxia Charlevoix-Saguenay Type, Spinocerebellar Ataxia Type 5, Spinocerebellar Ataxia Type 4, and Spasticity.

 
 
 
 
Learn about our expert tiers
Learn More
Advanced in Spastic Ataxia Charlevoix-Saguenay Type
Advanced in Spastic Ataxia Charlevoix-Saguenay Type

The Medical College Of Wisconsin Inc

8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Karen Blindauer is a Neurologist in Milwaukee, Wisconsin. Dr. Blindauer is rated as an Advanced provider by MediFind in the treatment of Spastic Ataxia Charlevoix-Saguenay Type. Her top areas of expertise are Movement Disorders, Parkinson's Disease, Essential Tremor, and Huntington Disease. Dr. Blindauer is currently accepting new patients.

What are the latest Spastic Ataxia Charlevoix-Saguenay Type Clinical Trials?
Coordination of Rare Diseases at Sanford

Summary: CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, in...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Who are the sources who wrote this article ?

Published Date: February 01, 2020
Published By: National Institutes of Health